NCCN Oncology Research Program Awards Grants for Innovative Prostate Cancer Research Involving Relugolix

National Comprehensive Cancer Network

PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has recently announced the awarding of grants for the development of innovative investigator-initiated research centered around the medication relugolix. The funding, supported by Pfizer Global Medical Grants and Sumitomo Pharma America, Inc., is aimed at advancing scientific knowledge regarding combination therapies for patients with advanced prostate cancer.

Relugolix is a GnRH antagonist indicated for the treatment of adult patients with advanced prostate cancer. It is the only approved oral androgen deprivation therapy (ADT) for this indication. The effectiveness of combining additional therapies with ADT has been established in the treatment of various stages of advanced prostate cancer.

“The aim of this project is to develop studies that will advance scientific knowledge regarding combination therapies that include relugolix in the treatment of patients with advanced prostate cancer,” said Dr. Crystal S. Denlinger, Chief Executive Officer, NCCN. “Congratulations to these inspiring investigators. Their research will help us learn more about how to care for people with advanced prostate cancer.”

The selected projects, set to be completed within five years, are led by top-tier researchers from renowned institutions such as Dana-Farber Cancer Institute, Winship Cancer Institute of Emory University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences. The research topics range from exploring the comeback from Long Course ADT with Relugolix and Darolutamide in Hormone-Sensitive Prostate Cancer to a Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant/Adjuvant to Local-regional Treatment in Patients with High-risk Locally Advanced Prostate Cancer.

READ:  Daniel M. Geynisman Takes Helm as Editor-in-Chief of JNCCN

Approximately $3.5 million in funding will be provided across all grants, representing a significant investment in advancing the field of oncology. These projects were selected through a rigorous peer-review process by a Scientific Review Committee, comprising leading expert oncologists from NCCN Member Institutions.

The NCCN ORP is committed to fostering innovation and knowledge discovery that improve the lives of people with cancer, supporting preclinical, translational, and clinical research, and quality improvement projects in oncology at NCCN Member Institutions. The awarded grants are a testament to this commitment and are expected to make significant contributions to the treatment of advanced prostate cancer.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.